Ollin Data Suggests IBI324 Outperforms Vabysmo in Retinal Disease
Event summary
- A Phase 1b head-to-head study (JADE) showed Ollin’s IBI324 (developed in collaboration with Innovent) demonstrated superior anatomic outcomes in diabetic macular edema (DME) compared to Vabysmo.
- IBI324 demonstrated numerically greater vision gains and fewer retreatments than Vabysmo in both DME and wet age-related macular degeneration (wAMD).
- New data revealed IBI324 achieved faster and greater reductions in pigment epithelial detachment (PED) thickness in wAMD patients compared to Vabysmo.
- Ollin and Innovent plan to initiate global Phase 3 clinical trials for IBI324 in DME and wAMD in 2026, targeting North America, South America, Europe, Japan, China, and South Korea.
The big picture
The ophthalmology market for retinal diseases is a multi-billion dollar space dominated by a handful of key players. Ollin’s IBI324 represents a potential disruption, offering a differentiated mechanism of action and improved efficacy profile compared to existing treatments. The success of the upcoming Phase 3 trials will be crucial in determining whether IBI324 can establish a significant market share and impact Innovent’s overall revenue trajectory.
What we're watching
- Regulatory Approval
- The speed of Phase 3 enrollment and subsequent regulatory approval will be critical for Ollin and Innovent to capitalize on the observed efficacy advantages over Vabysmo.
- Market Adoption
- Whether physicians will readily adopt IBI324 as a first-line treatment option, despite the promising data, will depend on pricing, reimbursement, and established treatment protocols.
- Competitive Response
- The response from Regeneron, the manufacturer of Vabysmo, and other competitors in the retinal disease space will be important to monitor, as they may accelerate development of next-generation therapies.
Related topics